APE1、XRCC1基因多态性对肝癌易感性及铂类药物敏感性的影响  

Single-nucleotide polymorphisms in DNA repair genes APE1 and XRCC1 and susceptibility to hepatocellular carcinoma and their correlation with sensitivity of platinum chemotherapy in HCC

作　　者：方壮伟[1] 梁茱[1] 吴宁[1] 邱纯[1] 林福煌[1] 袁波[1] 彭永红[1] 符勇[1] 周卫平[1] 周开伦[1] 谢贤和[1] 

机构地区：[1]海南省人民医院,海口570311

出　　处：《军事医学》2014年第1期48-52,共5页Military Medical Sciences

基　　金：海南省自然科学基金资助项目(808287)

摘　　要：目的：探讨APE1、XRCC1基因多态性对肝细胞癌（简称肝癌， HCC ）易感性的关系，同时探讨APE1、XRCC1基因多态性对HCC对铂类药物敏感性的影响。方法以2008年1月至2010年8月在我院住院治疗的HCC患者78例为病例组，以同期在我院因患肿瘤之外的其他疾病而住院治疗的患者80例为对照组。通过PCR及RFLP分析APE1 Asp148 Glu及XRCC1 Arg194 Trp基因单核苷酸多态与HCC易患风险及对铂类药物敏感的关系。结果 APE1 Asp148Glu 的Glu/Glu 基因型携带者患HCC 的风险上升6．21倍（95％CI：1．325～29．109）（P ＜0．05）；与Asp/Asp和Arg/Arg基因型携带者相比，Glu/Glu基因型携带者对铂类药物产生耐药性风险上升12．80倍（95％CI：1．149～142．771）；XRCC1 Arg194Trp 基因的Arg/Trp 基因型携带者对铂类药物产生耐药性风险上升9．375倍（95％CI：1．299～67．645）。结论 APE1 Asp148Glu 单核苷酸多态性与 HCC 的易感性有关；APE1 Asp148 Glu及XRCC1 Arg194 Trp单核苷酸多态性均可影响HCC细胞对铂类化疗药物的耐药性。Objective To investigate the relationship between APE1, XRCC1 gene polymorphisms and hepatocellular carcinoma（HCC） susceptibility and to explore the correlation of APE1, XRCC1 gene polymorphisms with the sensitivity to platinum-based drugs .Methods Seventy-eight HCC patients and 80 controls were selected .By PCR and RFLP , the single nucleotide polymorphism of APE1 Asp148Glu and XRCC1 Arg194Trp genes and the susceptibility of HCC or platinum drug sensitivity were analyzed.Results The Glu/Glu genotype of APE1 could increase in the risk of HCC by 7.21 times （95%CI：1.325-29.109） （P〈0.05）.APE1 and XRCC1 gene polymorphisms could also affect the platinum drug resistance of HCC patients.Conclusion APE1 Asp148Glu is correlated with the susceptibility to HCC .APE1 and XRCC1 genes can be considered a target for therapy to improve the sensitivity of HCC platinum drugs .

关 键 词：基因多态性 肝细胞癌 易感 铂类药物敏感性 

分 类 号：R735.7[医药卫生—肿瘤]